The combination of emtricitabine (EMT) and tenofovir (TEN) has recently been introduced in the market. Chemically emtricitabine\[[@CIT1]\] is 4-amino-5-fluoro-1-\[2-(hydroxymethyl)-1,3-oxathiolan-5-yl\]- pyrimidin-2-one. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults. Tenofovir\[[@CIT2]\] is 1-(6-aminopurin-9-yl) propan-2-yl-oxymethylphosphonic acid. It is nucleotide analogue reverse transcriptase inhibitor (NRTI). Literature survey reveals that, so far no HPTLC method has been reported for the simultaneous estimation of EMT and TEN in formulation. There is only one HPLC method reported\[[@CIT3]\] for this combination and it requires solid phase extraction of drugs from plasma; the total run time for this method is 18 min, which is quite a long time. Several methods were reported\[[@CIT4][@CIT5]\] for the individual estimation of EMT and TEN but not for the combined form. If the reported individual methods are applied for the analysis of the tablets containing EMT and TEN, it would require double time for analysis; the method would not be rapid, less expensive, whereas the developed HPTLC method for simultaneous estimation of the ingredients of tablets would save analysis time and economy. In the present investigation, an attempt has been made to develop a rapid, accurate, precise and cost effective HPTLC method for simultaneous estimation of EMT and TEN in combined dosage form.

EMT and TEN standards were procured as a gift samples from Cipla Pharmaceuticals Ltd. Silica gel 60 F~254~ TLC plates (20×10 cm, layer thickness 0.2 mm, E. Merck) were used as stationary phase. All chemicals and reagents used were of analytical grade and obtained from Qualigens. Marketed formulation Tenvir EM, manufactured by Cipla, India Ltd., containing EMT (200 mg) and TEN (300 mg), was used for the analysis. The instrument used in the present study was Camag HPTLC system comprising of Camag Linnomate V automatic sample applicator, Hamilton syringe (100 μl), Camag TLC Scanner 3, Camag Win CATS software, Camag Twin-trough chamber (20×10 cm). Ultrasonicator was used for extraction of the drugs from the tablets.

EMT and TEN (10 mg each) were weighed accurately, dissolved and diluted with methanol to obtain the final concentration of 0.1 μg/μl of each drug. From this solution 1ml o is diluted to 10 ml to get 100 ng/ml. Twenty tablets were weighed accurately and ground to fine powder. Weights equivalent to 10 mg of EMT and TEN were transferred to conical flask and mixed with methanol. The solution was sonicated for 15 min. The solution was centrifuged for 20 minutes and transferred to a 10 ml volumetric flask and volume was made up to 10 ml with methanol. Required dilutions were made to get 100 μg/ml of EMT and TEN.

To carry out HPTLC analysis\[[@CIT6]\], the TLC plates were prewashed with methanol. Activation of plates was done in an oven at 50° for 5 min. The chromatographic conditions maintained were precoated silica gel 60F~254~ aluminum sheets (20×10 cm) as stationary phase, chloroform:methanol (9:1 v/v) as mobile phase, chamber and plate saturation time of 30 min, migration distance allowed was 80 mm, wavelength scanning was done at 265 nm keeping the slit dimension at 6×0.45 mm. Five microlitres of standard solutions of EMT and TEN were spotted and developed at constant temperature. Wavelength was selected by scanning standard solutions of both drugs over 200 nm to 400 nm wavelengths. EMT showed maximum absorbance at 286 nm and TEN at 264 nm. Both components showed reasonably good response at 265 nm, therefore photometric measurements were performed at 265 nm in absorption mode with Camag TLC scanner 3 using Win CATS software. Aliquots of 2.0, 4.0, 6.0, 8.0, 10.0 μl of standard solutions of EMT and TEN were applied on the TLC plate (0.1 μg/ml of drug). TLC plate was dried, developed and analyzed photometrically as described earlier.

The developed method was validated\[[@CIT7][@CIT8]\] in terms of linearity, accuracy, limit of detection, intra-day and inter-day precision and repeatability of peak area measurement and the observations are reported in [Table 1](#T0001){ref-type="table"}. Linearity was measured in concentration range of 200-1000 ng/ml. Limit of detection was found 100 ng/spot and 50 ng/spot for EMT and TEN, respectively. Limit of quantification was found 160 ng /spot for EMT and 190 ng /spot for TEN. Precision was checked by repeatability of peak area measurement and RSD values were 0.21 for EMT and 0.19 for TEN. The method is specific for the above drugs, as the excipients do not interfere with the peaks of EMT and TEN.

###### 

METHOD VALIDATION PARAMETERS

  Parameters                     Values        
  ------------------------------ ------------- -------------
  Linearity range (ng/spot)      200-1000      200-1000
  Correlation coefficient (r)    0.9995        0.9996
  Regression equation (y=mx+c)                 
  Slope                          6.82          6.29
  Intercept                      117.3         18.81
  Limit of detection             100 ng/spot   50 ng/spot
  Limit of quantification        160 ng/spot   190 ng/spot
  Precision (%RSD)                             
  Repeatability of peak area                   
  measurement (n=5)              0.21          0.19

Twenty tablets were weighed accurately and ground to fine powder. Weights equivalent to 10 mg of EMT and TEN, were transferred to conical flasks and mixed with methanol. The solution was sonicated for 15 min. The solution was centrifuged for 20 minutes and transferred to a 10 ml volumetric flask and volume was made up to 10 ml with methanol. Required dilutions were made to get 100 μg/ml of EMT and TEN.

Accuracy parameter was checked by recovery studies. For EMT 99.54% recovery and for TEN 99.69% recovery was observed. Four micro litres of sample solutions of the marketed formulation were spotted on to the same TLC plate and developed. The analysis was repeated in triplicate. The content of the drug was calculated from the peak areas recorded.

The mobile phase consisting of chloroform: methanol (9:1 v/v) gave R~f~ values of 0.18±0.01 and 0.48±0.01 for EMT and TEN, respectively, with dense and compact spots desired for quantification of EMT and TEN in pharmaceutical formulations. ([fig. 1](#F0001){ref-type="fig"}) Calibration curve was obtained in the range of 200-1000 ng/ml with r^2^ value of 0.9995 and 0.9996 for EMT and TEN, respectively. Drug found by the assay of tablets was 100.16% and 99.94% for EMT and TEN, respectively. Accuracy parameter was checked by recovery studies. For EMT 99.54% recovery and for TEN 99.69% recovery was observed. Limit of detection was found to be 100 ng/spot and 50 ng/spot for EMT and TEN, respectively. Limit of quantification was found to be 160 ng/spot for EMT and 190 ng/spot for TEN. Thus, this method can routinely be applied for analysis of tablets.

![A typical HPTLC chromatogram of EMT and TEN](IJPhS-71-95-g001){#F0001}

The linear regression data\[[@CIT9]\] (n=5) showed a good linear relationship over a concentration range of 200-1000 ng/spot and for EMT and TEN, respectively. The limit of detection for EMT was found to be 100 ng/spot and for TEN, 50 ng/spot, The intra-day precision was determined by analyzing standard solutions in the concentration range of 100 ng/spot to 500 ng/spot for EMT and TEN for 3 times on the same day, while inter-day precision was determined by analyzing corresponding standards daily for 3 day over a period of one week. Repeatability of sample application was assessed by spotting 4 μl of drug solution, 5 times on a TLC plate, followed by development of plate and recording the peak area for 5 spots. The % RSD for peak area values of EMT and TEN were found to be 0.21 and 0.19, respectively. To confirm the specificity of the proposed method, the solution of the formulation was spotted on the TLC plate, developed and scanned. It was observed that the excipients present in the formulation did not interfere with the peaks of EMT and TEN.

Recovery studies of the drugs were carried out for the accuracy parameter. These studies were carried out at three levels, i.e. multiple level recovery studies (n=3). Sample stock solution from tablet formulation of 100 μg/ml was prepared. Dilutions were made and recovery studies were performed. Percent recovery was found to be within the limits as listed in [Table 2](#T0002){ref-type="table"}. The assay value for the marketed formulation was found to be within the limits as listed in [Table 3](#T0003){ref-type="table"}. The low RSD value indicated the suitability of the method for routine analysis of EMT and TEN in pharmaceutical dosage forms. The developed HPTLC technique is simple, precise, specific and accurate and the statistical analysis proved that method is reproducible and selective for the analysis of EMT and TEN in bulk drug and tablet formulations.

###### 

RECOVERY STUDIES OF EMT AND TEN

  Label Claim   Total Amt. added   Amt. Recovered   \% Recovery
  ------------- ------------------ ---------------- -------------
  EMT 20        1.6                1.586            99.17
                2.0                1.991            99.88
                2.4                2.385            99.59
  TEN 30        2.6                2.592            99.93
                3.0                3.002            100.08
                3.4                3.368            99.07

###### 

ANALYSIS OF EMT AND TEN

  Drugs   Rf     Amount found   \% drug recovered   r^2^     Standard deviation
  ------- ------ -------------- ------------------- -------- --------------------
  EMT     0.18   200.33 mg      100.16              0.9995   1.70
  TEN     0.47   299.84 mg      99.94               0.9996   1.77
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